Ticker	Volume	Price	Price Delta
DJIA	15,303.10	+8.60	0.06%
S&P 500	1,649.60	-0.91	-0.06%
Nasdaq	3,459.14	-0.27	-0.01%

Ticker

Volume

Price

Price Delta

DJIA

15,303.10

+8.60

0.06%

S&P 500

1,649.60

-0.91

-0.06%

Nasdaq

3,459.14

-0.27

-0.01%

Ticker	Volume	Price	Price Delta
STOXX 50	2,764.29	-12.49	-0.45%
FTSE 100	6,654.34	-42.45	-0.63%
DAX	8,305.32	-46.66	-0.56%

Ticker

Volume

Price

Price Delta

STOXX 50

2,764.29

-12.49

-0.45%

FTSE 100

6,654.34

-42.45

-0.63%

DAX

8,305.32

-46.66

-0.56%

Ticker	Volume	Price	Price Delta
Nikkei	14,612.50	+128.47	0.89%
Hang Seng	22,618.70	-51.01	-0.23%
S&P/ASX 200	4,983.50	-78.95	-1.56%

Ticker

Volume

Price

Price Delta

Nikkei

14,612.50

+128.47

0.89%

Hang Seng

22,618.70

-51.01

-0.23%

S&P/ASX 200

4,983.50

-78.95

-1.56%

Exchange: ASE
Sector: Consumer, Non-cyclical
Industry: Healthcare-Products
Sub-Industry: Medical Products

Cochlear Ltd

+ Add to Watchlist

COH:AU

65.2100 AUD 1.9100 2.85%

Share this quote:

Post this quote on one of these sites:

Copy permanent URL

As of 02:10:31 ET on 05/24/2013.

Snapshot for Cochlear Ltd (COH)

Open:	66.7000	Day's Range:	64.6400 - 67.1000	Volume:	449,916
Previous Close:	65.2100	52wk Range:	58.9400 - 82.8700	1-Yr Rtn:	+9.35%

Stock Chart for COH

No chart data available.

COH:AU 65.2100

65.2100

Interactive COH Chart

…

Previous Close

Key Statistics for COH

Current P/E Ratio (ttm)	23.9303
Estimated P/E(06/2013)	23.8080
Relative P/E vs. AS51	1.1814
Earnings Per Share (AUD) (ttm)	2.7250
Est. EPS (AUD) (06/2013)	2.7390
Est. PEG Ratio	3.3067
Market Cap (M AUD)	3,719.64
Shares Outstanding (M)	57.04
30 Day Average Volume	372,047
Price/Book (mrq)	9.5091
Price/Sale (ttm)	5.1367
Dividend Indicated Gross Yield	4.45%
Cash Dividend (AUD)	1.2500
Last Dividend	02/21/2013
5 Year Dividend Growth	12.30%
Next Earnings Announcement	08/06/2013

mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for COH

Revenue
Net Income (M/AUD)

Profit Margin (%)

Company Profile & Key Executives for COH

Cochlear Limited researches, develops and markets cochlear implant systems for hearing impaired individuals. The Company's hearing implant systems include Nucleus and Baha and are sold both domestically and internationally.